Research programme: tregitopes - EpiVax

Drug Profile

Research programme: tregitopes - EpiVax

Alternative Names: Albumin-tregitope; Epi-13

Latest Information Update: 24 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiVax
  • Developer EpiVax; Novozymes A/S
  • Class Immunoglobulin fragments; Peptides
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypersensitivity; Type 1 diabetes mellitus
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Glycogen storage disease type II

Most Recent Events

  • 24 Jul 2016 Preclinical development in Type-1 diabetes mellitus and Hypersensitivity is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Chronic inflammatory demyelinating polyradiculoneuropathy in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Glycogen-storage-disease-type-II in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top